新型冠状病毒肺炎抗病毒药物临床研究进展

新型冠状病毒(2019-nCoV或SARS-CoV-2)是一种传染性强、致死率较高的病毒，目前已造成全球25个国家的5万余人感染，1千余人死亡。人感染新型冠状病毒后可出现发热和咳嗽等症状，部分患者可出现呼吸困难等严重症状，重症患者可出现急性呼吸窘迫综合征和脓毒症休克而导致死亡。目前国内外尚无针对新型冠状病毒肺炎明确有效的抗病毒药物。因此，本文拟通过对近期国内外针对新型冠状病毒肺炎的抗病毒药物基础研究和临床进展进行综述，为临床更加有效地治疗新型冠状病毒肺炎提供新的思路。;The novel coronavirus (2019-nCoV or SARS-CoV-2) is a highly contagious and deadly virus that has infected more than 50 000 people and killed more than 1 000 people in 25 countries around the world. People who infected with the novel coronavirus may suffer from fever and cough, some may gradually experience breathing difficulties and other serious manifestations, some severe patients may have acute respiratory distress syndrome and septic shock leading to death. However, there are no definite and effective antiviral drugs for the novel coronavirus pneumonia all around the world. Therefore, this article aims to provide new idea for the effective treatment of the novel coronavirus pneumonia by summarizing the basic research and clinical progress of antiviral drugs at home and abroad.